Verve Therapeutics, Inc. - Common Stock
Verve Therapeutics, Inc. - Common Stock
Share · US92539P1012 · VERV (XNAS)
Overview Financial Indicators
6,17 USD
4,58 % 0,27 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
06.06.2025 23:48

Current Prices from Verve Therapeutics, Inc. - Common Stock

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
VERV
USD
06.06.2025 23:48
6,17 USD
5,73 USD
+7,68 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 36,26 % 41,51 % -6,66 % -4,64 % 16,86 % -80,67 %

Company Profile for Verve Therapeutics, Inc. - Common Stock Share

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Company Data

Name Verve Therapeutics, Inc. - Common Stock
Company Verve Therapeutics, Inc.
Symbol VERV
Website https://www.vervetx.com
Primary Exchange XNAS NASDAQ
ISIN US92539P1012
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Sekar Kathiresan M.D.
Market Capitalization 409 Mio
Country United States of America
Currency USD
Employees 0,3 T
Address 500 Technology Square, 02139 Cambridge
IPO Date 2021-06-17

Ticker Symbols

Name Symbol
NASDAQ VERV

More Shares

Investors who Verve Therapeutics, Inc. - Common Stock hold also have the following shares in their portfolio:
AGIF-GL.SUSTAIN.A DL
AGIF-GL.SUSTAIN.A DL Fund
REPUBLIC OF GHANA (THE) 8.950% AMORTISING NTS 26/03/51 (144A)
REPUBLIC OF GHANA (THE) 8.950% AMORTISING NTS 26/03/51 (144A) Bond
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025